The Broad Spectrum Receptor Tyrosine Kinase Inhibitor Dovitinib Suppresses Growth of BRAF Mutant Melanoma Cells in Combination with Other Signaling Pathway Inhibitors

BRAF inhibitors have revolutionized treatment of mutant BRAF metastatic melanomas. However, resistance develops rapidly following BRAF inhibitor treatment. We have found that BRAF-mutant melanoma cell lines are more sensitive than wild-type BRAF cells to the small molecule tyrosine kinase inhibitor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pigment Cell Melanoma Res
Main Authors: Langdon, Casey G., Held, Matthew A., Platt, James T., Meeth, Katrina, Iyidogan, Pinar, Mamillapalli, Ramanaiah, Koo, Andrew B., Klein, Michael, Liu, Zongzhi, Bosenberg, Marcus W., Stern, David F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215495/
https://ncbi.nlm.nih.gov/pubmed/25854919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12376
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados